

NCT	Drug	Cancer	Reason Excluded	Start Year	
Canada	Ipilimumab	Cervical	NO RACE	2012	
JapicCTI-163212	Nivolumab	Cervical	NO RACE	2016	
JapicCTI-163212	Nivolumab	Uterine	NO RACE	2016	
NCT00729664	PD-L1	Breast	NO RACE	2008	
NCT00729664	PD-L1	Ovarian	NO RACE	2008	
NCT01042379	Multiple	Breast		2010	
NCT01237236	PD-L1 Atezolizumab	Breast	See Comment	2010	Provides racial breakdown of ALL participants, but not by cancer site
NCT01237236	PD-L1 Atezolizumab	Ovarian	See Comment	2010	Provides racial breakdown of ALL participants, but not by cancer site
NCT01266460	Vaccine	Cervical		2010	
NCT01375842	Atezolizumab	Breast	NO RACE	2011	
NCT01375842	Atezolizumab	Cervical	NO RACE	2011	
NCT01375842	Atezolizumab	Uterine	NO RACE	2011	
NCT01551745	Vigil + Vaccine	Ovarian		2012	
NCT01585428	Tumor Infiltrating Lymphocytes	Cervical		2012	
NCT01611558	Ipilimumab	Ovarian		2012	
NCT01633970	Atezolizumab	Breast		2012	
NCT01642082	Dalantercept	Uterine		2012	
NCT01772004	PD-L1 Avelumab	Breast	See Comment	2013	Provides racial breakdown of ALL participants, but not by cancer site
NCT01772004	PD-L1 Avelumab	Cervical	Less than 4 patients.	2013	Provides racial breakdown of ALL participants, but not by cancer site
NCT01772004	PD-L1 Avelumab	Ovarian		2013	
NCT01848834	Pembrolizumab	Breast		2013	
NCT01876511	Pembrolizumab	Uterine	See Comment	2013	Provides racial breakdown of ALL participants, but not by cancer site
NCT02054806	Pembrolizumab	Breast		2014	
NCT02054806	Pembrolizumab	Cervical		2014	
NCT02054806	Pembrolizumab	Ovarian		2014	
NCT02054806	Pembrolizumab	Uterine		2014	
NCT02129556	Anti PD-1	Breast		2014	
NCT02129556	Anti PD 1	Breast		2014	
NCT021819518	Pembrolizumab + Chemo	Breast		2016	
NCT02257528	Nivolumab	Cervical		2015	
NCT02309177	Nivolumab	Breast	See Comment	2014	Provides racial breakdown of ALL participants, but not by cancer site
NCT02346747	Vigil	Ovarian		2015	
NCT02403271	Anti PD 1	Breast		2015	
NCT02425891	Atezolizumab + Paclitaxel	Breast		2015	
NCT02428192	Nivolumab +/- Ipilimumab	Uterine		2015	
NCT02447003	Pembrolizumab	Breast		2015	
NCT02488759	Nivolumab	Cervical		2015	
NCT02498600	Nivolumab +/- Ipilimumab	Ovarian		2015	
NCT02501096	Lenvatinib + pembrolizumab	Uterine		2015	
NCT02513472	Pembrolizumab + Eribulin Mesylate	Breast		2015	
NCT02537444	Acalabrutinib vs Acalabrutinib vs Pembrolizumab	Ovarian		2015	
NCT02555657	Pembrolizumab	Breast		2015	
NCT02580058	Chemo +/- Avelumab	Ovarian		2015	
NCT02608684	Pembrolizumab + Standard Treatment	Ovarian		2015	

NCT02622074	Pembrolizumab	Breast		2016	
NCT02622074	Pembrolizumab + Chemo	Breast		2015	
NCT02628067	Pembrolizumab	Cervical		2015	Interim Results
NCT02649686	Durvalumab +/- Olaparib	Breast	NO RACE	2016	
NCT02657889	Pembrolizumab + Niraparib	Breast		2016	
NCT02657889	Pembrolizumab + Niraparib	Ovarian		2016	
NCT02685059	Durvalumab	Breast	NO RACE	2016	
NCT02718417	Chemo +/- Avelumab	Ovarian		2016	
NCT02734004	Durvalumab +/- Olaparib	Breast		2016	
NCT02853318	Pembrolizumab + Bevacizumab + Cyclophosphamide	Ovarian		2016	
NCT02924883	Atezolizumab	Breast		2016	
NCT03036488	Pembrolizumab	Breast	NO RACE	2017	
NCT03125902	Atezolizumab	Breast		2017	
NCT03197935	Nivolumab	Breast		2017	
NCT03287674	Ipilimumab	Ovarian	NO RACE	2017	